Design and study sample
Cancer, breast cancer
CANCER, BREAST CANCER
In this phase II, single‐arm trial, we recruited 56 patients scheduled to begin neo/adjuvant chemotherapy for stage I–III breast cancer at the University of North Carolina (UNC) Health System's North Carolina Cancer Center, Hillsborough Hospital, and Rex Cancer Center between September 2019 and August 2021. Participants completed a cognitive assessment prior to initiating chemotherapy (pre‐) and 4 weeks after (post‐) their final cycle. Memantine was administered twice daily (BID) between pre‐ and post‐assessments. The study was approved by the UNC Institutional Review Board and UNC Lineberger Protocol Review Committee. The trial is registered at 